Research programme: fibrotic disease therapeutics - Ergon Pharmaceuticals
Latest Information Update: 28 Mar 2024
At a glance
- Originator Ergon Pharmaceuticals
- Class Antifibrotics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for research development in Idiopathic-pulmonary-fibrosis in USA